Compare LWLG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWLG | PRTA |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.6M | 482.3M |
| IPO Year | 2011 | 2013 |
| Metric | LWLG | PRTA |
|---|---|---|
| Price | $7.17 | $9.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.9M | 416.4K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $95,605.00 | ★ $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 136.05 | N/A |
| 52 Week Low | $0.79 | $4.32 |
| 52 Week High | $6.26 | $14.34 |
| Indicator | LWLG | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 74.92 | 50.68 |
| Support Level | $3.08 | $8.23 |
| Resistance Level | N/A | $9.59 |
| Average True Range (ATR) | 0.58 | 0.50 |
| MACD | 0.20 | 0.06 |
| Stochastic Oscillator | 89.00 | 50.14 |
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.